Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Federico Nichetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8044-4207; OpenAlex author ID A5071355244. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  2. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  3. Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN. Co-author DOI 10.1200/jco-25-01517↗
  4. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… First author DOI 10.1016/j.dld.2025.11.007↗
  5. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1001/jamanetworkopen.2023.50756↗
  6. Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Co-author DOI 10.1002/cam4.70393↗
  7. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … Co-author DOI 10.3390/cancers11040484↗
  8. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. Co-author DOI 10.1007/s11523-018-0567-0↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Monica Niger · 6 shared papers, 2019–2026 · strength 0.97
  2. Francesca Bergamo · 3 shared papers, 2025–2026 · strength 0.79
  3. Letizia Procaccio · 2 shared papers, 2026 · strength 0.63
  4. Sara Lonardi · 2 shared papers, 2026 · strength 0.63
  5. Caterina Vivaldi · 3 shared papers, 2025–2026 · strength 0.57
  6. Vincenzo Mazzaferro · 3 shared papers, 2024–2026 · strength 0.54
  7. Sara Pusceddu · 4 shared papers, 2018–2024 · strength 0.49
  8. Mario Scartozzi · 2 shared papers, 2026 · strength 0.41
  9. Andrea Pretta · 2 shared papers, 2026 · strength 0.41
  10. Giampaolo Tortora · 2 shared papers, 2026 · strength 0.41
  11. Carolina Sciortino · 2 shared papers, 2025–2026 · strength 0.37
  12. Lisa Salvatore · 2 shared papers, 2025–2026 · strength 0.37
  13. Elisa Giommoni · 2 shared papers, 2025–2026 · strength 0.36
  14. Gianluca Tomasello · 2 shared papers, 2019–2025 · strength 0.24
  15. P. Andena · 1 shared paper, 2026 · strength 0.21
  16. Chiara Carmen Miceli · 1 shared paper, 2026 · strength 0.20
  17. Simona Casalino · 1 shared paper, 2026 · strength 0.20
  18. Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.20
  19. Ferdinando De Vita · 1 shared paper, 2026 · strength 0.20
  20. Guido Giordano · 1 shared paper, 2026 · strength 0.20
  21. Matteo Landriscina · 1 shared paper, 2026 · strength 0.20
  22. Giuseppe Aprile · 1 shared paper, 2026 · strength 0.20
  23. Roberto Bianco · 1 shared paper, 2026 · strength 0.20
  24. Davide Melisi · 1 shared paper, 2026 · strength 0.20
  25. Enrico Vasile · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.